Cagrilintide vs Retatrutide
Both Cagrilintide and Retatrutide are kept in stock here and are frequently weighed against each other. This page lays out where they diverge: how each is classed, what sizes exist and the per-milligram price, the shape of the evidence published on each, and how Canadian law treats them. It draws no ranking between them, since which one fits turns on what is being studied.
Side by side
| Cagrilintide | Retatrutide | |
|---|---|---|
| Class | Long-acting amylin analogue (amylin receptor agonist) | GIP, GLP-1 and glucagon receptor agonist |
| Sizes and price | 5 mg · 10 mg — from $43.00 (best $8.55/mg) | 10 mg · 20 mg · 30 mg — from $87.00 (best $6.60/mg) |
| Published evidence | 8 cited studies; 8 controlled trials in people. | 6 cited studies; 6 controlled trials in people. |
| Models studied | human | human |
| Status in Canada | No Drug Identification Number | No Drug Identification Number; named in a Health Canada advisory |
| Formats | vial, starter | vial, pen, starter, kit, value |
Key differences
The evidence on record, Cagrilintide: 8 cited studies; 8 controlled trials in people. And Retatrutide: 6 cited studies; 6 controlled trials in people.
No published study has set Cagrilintide against Retatrutide head to head. The figures above come from separate studies of each compound, so the two columns are not the output of a single experiment.
Both are provided strictly for in-vitro laboratory research, and neither is meant for human or veterinary use.
FAQ
How do Cagrilintide and Retatrutide differ?
Cagrilintide is long-acting amylin analogue (amylin receptor agonist), whereas Retatrutide is gip, glp-1 and glucagon receptor agonist. The table above breaks down each size, the per-milligram price, the evidence behind each compound and where each stands in Canada.
Which of Cagrilintide and Retatrutide has more published research?
Cagrilintide lists 8 cited studies on its page and Retatrutide lists 6. A higher count is not a mark of quality: the model behind each study counts for more, and both pages record that for every paper.
Are Cagrilintide and Retatrutide authorized for sale in Canada?
For Cagrilintide: No Drug Identification Number. For Retatrutide: No Drug Identification Number; named in a Health Canada advisory. Health Canada authorizes a drug by assigning an eight-digit Drug Identification Number, and most research peptides hold none.
Can Cagrilintide and Retatrutide be combined?
No published study has examined the two in combination, so there is no evidence on what pairing them does. We supply both for laboratory research and make no claim about using them together.